Last reviewed · How we verify
Placebo by intravenously administration
Placebo has no active pharmacological mechanism; it produces therapeutic effects through psychological and psychophysiological processes.
Placebo has no active pharmacological mechanism; it produces therapeutic effects through psychological and psychophysiological processes. Used for Clinical research control / comparator in randomized controlled trials.
At a glance
| Generic name | Placebo by intravenously administration |
|---|---|
| Also known as | Saline by intravenously administration |
| Sponsor | Shenzhen Kangning Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebo administered intravenously acts through expectation, conditioning, and the patient's belief in treatment rather than through direct molecular interaction. The intravenous route may enhance the placebo effect by increasing perceived treatment intensity. This is typically used in clinical research settings to serve as a control comparator for evaluating the true efficacy of active pharmaceutical agents.
Approved indications
- Clinical research control / comparator in randomized controlled trials
Common side effects
- Nocebo effects (adverse events attributed to placebo expectation)
- Injection site reactions (from IV administration)
Key clinical trials
- A Study of LY4268989 (MORF-057) in Healthy Participants (PHASE1)
- Tranexamic Acid for The Treatment of Gastrointestinal Bleeding (NA)
- A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy (PHASE3)
- A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer (PHASE3)
- Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer (PHASE3)
- A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer (PHASE2)
- Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant (PHASE3)
- CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: